Unconventional T cell targets for cancer immunotherapy

Godfrey, Dale I., Le Nours, Jérôme, Andrews, Daniel M., Uldrich, Adam P. and Rossjohn, Jamie ORCID: https://orcid.org/0000-0002-2020-7522 2018. Unconventional T cell targets for cancer immunotherapy. Immunity 48 (3) , pp. 453-473. 10.1016/j.immuni.2018.03.009

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (462kB) | Preview

Abstract

Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Elsevier (Cell Press)
ISSN:	1074-7613
Date of First Compliant Deposit:	16 April 2019
Last Modified:	18 Nov 2024 07:00
URI:	https://orca.cardiff.ac.uk/id/eprint/117748

Citation Data

Cited 151 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item